CHRS.US Coherus BioSciences Inc

Healthcare Biotechnology USA Stocks
0.5255 USD
Close of Nov 14, 2026
0.5028 2.62
Market cap
USD 81.2M
P/E
-
P/B
3.28x
ROE
-517.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CHRS.US undervalued?

Graham number

The Graham number of Coherus BioSciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Coherus BioSciences Inc fundamental analysis

No fundamental analysis for Coherus BioSciences Inc yet.

Coherus BioSciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Coherus BioSciences Inc

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develop…

Full company profile